Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma
NCT07593040Phase 2Not yet recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of belzutifan in renal cell carcinoma (RCC), sponsored by Vall d'Hebron Institute of Oncology. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
belzutifan
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT07593040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593040.